Q-omics provides the consensus-scored LRRC38 profile across patient tissues and cancer cell-line models. LRRC38 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LRRC38 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LRRC38 RNA expression shows 15,611 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, KIRC, and ACC as cancer lineages where LRRC38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC38 survival associations across molecular data types. LRRC38 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC38 RNA expression–survival associations across cancer types. High LRRC38 expression shows unfavorable associations in KIRP, ACC, HNSC, KICH and LIHC, but favorable associations in CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LRRC38 RNA expression.
This table summarizes LRRC38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC38 shows lower tumor expression in KIRC, BRCA, BLCA and STAD and higher tumor expression in COAD and LUSC. The KIRC box plot shows higher LRRC38 RNA expression in normal versus tumor tissue (log2 FC = −0.202, t-test p < 0.001).
This table shows molecular features associated with LRRC38 in patient tissues and cancer cell lines. In patient samples, LRRC38 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
